Stay updated with breaking news from Activity Score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In the phase 2b ENLIVEN trial, the investigational drug pegozafermin met both primary endpoints at 24 weeks and led to improvements in fibrosis, paving the way for phase 3 development.
- Significant and rapid improvement in both signs and symptoms of TED after two infusions of 3 mg/kg, generally consistent with prior 10 and 20 mg/kg...
Both 50- and 28-mg doses improved fibrosis vs placebo, without worsening of NASH
- Clinical and in vitro data presented in three late-breaking presentations at ATA provide emerging evidence of VRDN-001 efficacy and differentiation
/PRNewswire/ -- Regeneron Pharmaceuticals (Nasdaq: REGN) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today preliminary Phase 1 data supporting...